Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Non-Current Assets (2016 - 2025)

Historic Non-Current Assets for UroGen Pharma (URGN) over the last 10 years, with Q3 2025 value amounting to $16.5 million.

  • UroGen Pharma's Non-Current Assets rose 14101.67% to $16.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $48.4 million, marking a year-over-year increase of 11338.57%. This contributed to the annual value of $9.6 million for FY2024, which is 494.25% up from last year.
  • UroGen Pharma's Non-Current Assets amounted to $16.5 million in Q3 2025, which was up 14101.67% from $11.8 million recorded in Q2 2025.
  • Over the past 5 years, UroGen Pharma's Non-Current Assets peaked at $17.0 million during Q1 2023, and registered a low of $2.9 million during Q2 2024.
  • Its 5-year average for Non-Current Assets is $9.0 million, with a median of $9.1 million in 2023.
  • As far as peak fluctuations go, UroGen Pharma's Non-Current Assets plummeted by 9038.68% in 2021, and later skyrocketed by 31128.08% in 2025.
  • UroGen Pharma's Non-Current Assets (Quarter) stood at $5.4 million in 2021, then increased by 25.32% to $6.7 million in 2022, then soared by 35.95% to $9.1 million in 2023, then rose by 4.94% to $9.6 million in 2024, then skyrocketed by 72.31% to $16.5 million in 2025.
  • Its Non-Current Assets was $16.5 million in Q3 2025, compared to $11.8 million in Q2 2025 and $10.4 million in Q1 2025.